<DOC>
	<DOCNO>NCT00568776</DOCNO>
	<brief_summary>The purpose study evaluate dose-related safety efficacy multiple oral dosage ELND005 treatment Alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>ELND005 Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>ELND005 ( formerly know AZD-103 ) , scyllo-inositol , investigate orally administer treatment AD . ELND005 may prevent inhibit build amyloid protein brain AD patient . This randomized , double-blind , placebo-controlled , dose-ranging , safety efficacy study oral ELND005 male female participant age 50-85 year mild moderate AD . Approximately 340 patient enrol study approximately 65 study site . Patients randomize receive either ELND005 placebo . Each patient 's participation last approximately 18 month .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>Diagnosis probable AD Age 50 85 year , inclusive MiniMental Status Exam ( MMSE ) score 1626 , inclusive Brain magnetic resonance imaging ( MRI ) scan consistent diagnosis AD Fluency English , French , Spanish Stable dose medication ( cholinesterase inhibitor memantine allow ) Caregiver able attend study visit Significant neurological disease AD Major psychiatric disorder Significant medical illness History stroke seizure History heart attack within last 2 year Prior treatment certain experimental medicine Presence pacemaker foreign metal object eye , skin , body would prevent patient MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>